These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8159104)

  • 21. Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM.
    McMahon M; Marsh HM; Rizza RA
    Diabetes; 1989 Mar; 38(3):291-303. PubMed ID: 2492963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake.
    Nielsen MF; Basu R; Wise S; Caumo A; Cobelli C; Rizza RA
    Diabetes; 1998 Nov; 47(11):1735-47. PubMed ID: 9792543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Important role of adrenergic mechanisms in acute glucose counterregulation following insulin-induced hypoglycemia in type I diabetes. Evidence for an effect mediated by beta-adrenoreceptors.
    Bolli G; de Feo P; Compagnucci P; Cartechini MG; Angeletti G; Santeusanio F; Brunetti P
    Diabetes; 1982 Jul; 31(7):641-7. PubMed ID: 6298039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
    Villaume C; Beck B; Kolopp M; Toussain P; Debry G
    Biomed Pharmacother; 1986; 40(2):61-4. PubMed ID: 2875745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normal proinsulin responses to glucose in mild type II subjects with subnormal insulin response.
    Levy JC; Clark PM; Hales CN; Turner RC
    Diabetes; 1993 Jan; 42(1):162-9. PubMed ID: 8420813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Normalization of insulin sensitivity in type I diabetic subjects by physical training during insulin pump therapy.
    Yki-Järvinen H; DeFronzo RA; Koivisto VA
    Diabetes Care; 1984; 7(6):520-7. PubMed ID: 6391876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.
    Wu H; Sui C; Xu H; Xia F; Zhai H; Zhang H; Weng P; Han B; Du S; Lu Y
    J Diabetes Res; 2014; 2014():524517. PubMed ID: 25580440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A high protein low fat meal does not influence glucose and insulin responses in obese individuals with or without type 2 diabetes.
    Papakonstantinou E; Triantafillidou D; Panagiotakos DB; Iraklianou S; Berdanier CD; Zampelas A
    J Hum Nutr Diet; 2010 Apr; 23(2):183-9. PubMed ID: 20113388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for increased liver glycogen in patients with noninsulin-dependent diabetes mellitus after a 3-day fast.
    Clore JN; Post EP; Bailey DJ; Nestler JE; Blackard WG
    J Clin Endocrinol Metab; 1992 Mar; 74(3):660-6. PubMed ID: 1740502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type 2 diabetes mellitus and the catabolic response to surgery.
    Schricker T; Gougeon R; Eberhart L; Wykes L; Mazza L; Carvalho G; Carli F
    Anesthesiology; 2005 Feb; 102(2):320-6. PubMed ID: 15681946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects.
    Sherwin RS; Fisher M; Hendler R; Felig P
    N Engl J Med; 1976 Feb; 294(9):455-61. PubMed ID: 1246330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
    Greenbaum CJ; Prigeon RL; D'Alessio DA
    Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucoregulation during and after intense exercise: effects of beta-adrenergic blockade in subjects with type 1 diabetes mellitus.
    Sigal RJ; Fisher SJ; Halter JB; Vranic M; Marliss EB
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3961-71. PubMed ID: 10566635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of long-term dietary protein intake on glucose metabolism in humans.
    Linn T; Santosa B; Grönemeyer D; Aygen S; Scholz N; Busch M; Bretzel RG
    Diabetologia; 2000 Oct; 43(10):1257-65. PubMed ID: 11079744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.
    Rizza R; Verdonk C; Miles J; Service FJ; Gerich J
    J Clin Invest; 1979 Jun; 63(6):1119-23. PubMed ID: 447838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects.
    Bogardus C; Lillioja S; Howard BV; Reaven G; Mott D
    J Clin Invest; 1984 Oct; 74(4):1238-46. PubMed ID: 6384267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12.
    Byrne MM; Sturis J; Menzel S; Yamagata K; Fajans SS; Dronsfield MJ; Bain SC; Hattersley AT; Velho G; Froguel P; Bell GI; Polonsky KS
    Diabetes; 1996 Nov; 45(11):1503-10. PubMed ID: 8866553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.